Slide 1: Long-Term Barzolvolimab Treatment Results in Sustained Off-Treatment Improvement in Angioedema
Long-Term Barzolvolimab Treatment Results in Sustained Off-Treatment Improvement in Scan QR code to view poster Angioedema in Patients With Chronic Spontaneous Urticaria Refractory to Antihistamines M. Metz,1,2 A. M. Giménez-Arnau,3 J. Peter,4 E. Mitha,5 J. Leflein,6 M. Gotua,7 B. Kwiek,8 H.Lu,9 D.
Slide 2: Long-Term Barzolvolimab Treatment Results in Sustained Off-Treatment Improvement in Angioedema
Long-Term Barzolvolimab Treatment Results in Sustained Off-Treatment Improvement in Angioedema in Patients With Chronic Spontaneous Urticaria Refractory to Antihistamines M. Metz,1,2 A. M. Giménez-Arnau,3 J. Peter,4 E. Mitha,5 J. Leflein,6 M. Gotua,7 B. Kwiek,8 H.Lu,9 D. Alvarado,9 D. Maurer,9 L. Du
Slide 3: Introduction
INTRODUCTION • Mast cells (MCs) are key effector cells that drive the development of itch, wheals, and angioedema in chronic spontaneous urticaria (CSU)1 • Angioedema impacts approximately 50% of patients with CSU and is associated with increased severity and duration of disease, as well as diminish
Slide 4: Study Design and Methods
STUDY DESIGN AND METHODS • This double-blind, placebo-controlled trial (NCT05368285) randomized patients to receive barzolvolimab subcutaneously at 75 mg every 4 weeks (Q4W), 150 mg Q4W, 300 mg every 8 weeks (Q8W), or placebo during a 16- week placebo-controlled treatment phase followed by 36 weeks
Slide 5: Study Design and Methods (Cont'd)
STUDY DESIGN AND METHODS (CONT’D) • AAS measures 5 dimensions of angioedema (duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity) for the past 24 hours. AAS7 comprises the sum of all AAS dimensions over a 7-day period with scores ranging from 0 to 10
Slide 6: Study Design and Methods (Cont'd): Baseline demographics
STUDY DESIGN AND METHODS (CONT’D) Baseline demographics and disease characteristics in patients with AAS7>0 at randomization Placebo Barzolvolimab 75 mg Barzolvolimab 150 mg Barzolvolimab 300 mg (n=32) (n=40) (n=35) (n=42) Age, y (SD) 40.2 (13.9) 40.7 (15.0) 43.4 (12.0) 48.1 (12.9) Female, n (%) 25
Slide 7: Barzolvolimab results in rapid improvements in angioedema sustained up to 28 weeks
Barzolvolimab treatment results in rapid improvements in angioedema that are sustained up to 28 weeks after the last dose Barzolvolimab treatment leads to sustained off-treatment improvement in angioedema Placebo-Controlled Period Active Treatment Period Follow-Up Period Placebo → (16 weeks) (36 wee
Slide 8: Angioedema-free status sustained in up to 64% of treated patients
Barzolvolimab treatment leads to angioedema-free status that is sustained in up to 64% of treated patients 28 weeks after the last dose 100 Placebo-Controlled Period Active Treatment Period Follow-Up Period (16 weeks) (36 weeks) (24 weeks) Placebo → angioedema-free status (AAS7=0) 150 mg Q4W % of pa
Slide 9: Conclusions
CONCLUSIONS • Among patients with moderate to severe antihistamine-refractory CSU and angioedema at baseline, treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema • In this Phase 2 trial of barzolvolimab, relief from angioedema symptoms began as early a
Slide 10: Thank You!
Scan QR code to view presentation THANK YOU!